Thursday, September 18, 2025 9/18/2025

Supplement to Pathogenesis of HIV-associated sensory neuropathy

Award Number: R01NS122571
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Supplement to Pathogenesis of HIV-associated sensory neuropathy - Project Summary HIV-1-associated sensory neuropathy (hHIV-SN) remains prevalent in antiretroviral therapy era, affecting 30-60% of 39.9 million HIV patients worldwide, also with 100% cases diagnosed with autopsy in HIV patients with chronic pain (hHIV-PAIN). We characterized protein gene product immunopositive (PGP9.5+) and growth associated protein immunopositive (GAP43+) nociceptors and investigated the mechanism for GAP43+ nociceptor sprouting in mouse. The parent R01 central hypothesis is: HIV-1 gp120 causes mHIV-SN by activation of Wnt5a-NGF mediated sprouting of the GAP43+ nociceptor, which in turn specifically mediates HIV-PAIN with three aims: 1. Investigate the interplay of the sprouting of GAP43+ and the degenerating of PGP9.5+ nociceptors. 2. Determine the activation of Wnt5a-NGF pathway mediated the sprouting of GAP43+ nociceptor. 3. Determine the therapeutic potential of antagonisms of Wnt5a, NGF in inhibiting sprouting and GDNF rebuilding healthy skin innervation. Finished works were submitted as year 1, 2, 3 progress reports, two corresponding author preprints and three meeting abstracts, including one sfn abstract. After 3.5 years awarded work, we defined the characteristics of sprouted GAP43+ and relevant mechanisms and studied how to target sprouting in mouse HIV-SN (mHIV-SN). The Proposed administrative supplement work is within the scope of parent R01: To visualize and track the dynamic changes of nociceptors in mHIV-SN, target the NGF to inhibit sprouting GAP43+, rebuid healthy skin innervation with GDNF, the PGP9.5+ dependent neurotrophic factor. Aim 1. To build up in vivo nociceptor visualizing platform and dynamically observe nociceptors changes. Aim 2. To investigate the gp120 induced upregulation of Wnt5a mediates NGF upregulation in spinal cord, DRG neurons and skin that all contribute to the GAP43+ ending sprouting. Aim 3. To examine the antagonism effects of NGF (tanezumab) in treating of mHIV-SN by inhibiting the sprouting of GAP43+ and rebuild healthy skin innervation by GDNF. The proposed work is innovative, because it represents a new and substantive progress in nociceptor research. Successfully finish the proposed work will provide novel concept that nociceptor sprouting is a critical mechanism for chronic HIV-PAIN, that contradicts to long time dominated nociceptor degeneration concept. The reason I apply the administration supplement is that I was diagnosed age-related macular degeneration (AMD) two years ago with decreasing vision. AMD has no FDA approval treatment until November 2024, a new therapy was approved that can significantly improve version. I scheduled a 12-month therapy that will begin two months later. I hope the application with 1.5-year award period, can effectively help me finish the therapy and bring me back to fully loaded work.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $480,000 )
2025	2025	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	9/8/2025	SUPPLEMENT FOR EXPANSION	$80,000
2025	2025	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	8/7/2025	NON-COMPETING CONTINUATION	$400,000
														Subtotal = $480,000

Issue Date FY: 2024 ( Subtotal = $400,000 )
2024	2024	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	8/16/2024	NON-COMPETING CONTINUATION	$400,000
														Subtotal = $400,000

Issue Date FY: 2023 ( Subtotal = $400,000 )
2023	2023	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	8/17/2023	NON-COMPETING CONTINUATION	$400,000
														Subtotal = $400,000

Issue Date FY: 2022 ( Subtotal = $400,000 )
2022	2022	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	7/25/2022	NON-COMPETING CONTINUATION	$400,000
														Subtotal = $400,000

Issue Date FY: 2021 ( Subtotal = $400,000 )
2021	2021	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	9/24/2021	NEW	$400,000
														Subtotal = $400,000

Grand Total All Awards = $2,080,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Supplement to Pathogenesis of HIV-associated sensory neuropathy

Award Number: R01NS122571

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer